Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL BECKER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1881741775
CMS profile
221106
Location
LUTHERVILLE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$215,638.63

397 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 6 of 8; records 251–300 of 397 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL BECKER

NPI 1881741775 · CMS profile ID 221106

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

LUTHERVILLE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 8; records 251–300 of 397 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881741775?year=2023&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL BECKER, NPI 1881741775, CMS profile ID 221106. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 8; records 251–300 of 397 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881741775?year=2023&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DANIEL BECKER, NPI 1881741775, CMS profile ID 221106. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 8; records 251–300 of 397 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881741775?year=2023&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DANIEL BECKER, NPI 1881741775, CMS profile ID 221106, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 8; records 251–300 of 397 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1881741775?year=2023&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

397 matching records · $215,638.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 397 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 397.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $251.9605/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014667215 CMS
PFIZER INC. $15.8205/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049233021 CMS
Biogen, Inc. $6.8905/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012185291 CMS
EMD Serono, Inc. $105.0805/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032346081 CMS
Genentech USA, Inc. $6.0505/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040335683 CMS
UPSHER-SMITH LABORATORIES LLC $23.3905/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 994136259 CMS
AbbVie Inc. $7.5405/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996225963 CMS
E.R. Squibb & Sons, L.L.C. $3,780.0005/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014667057 CMS
E.R. Squibb & Sons, L.L.C. $15.0005/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014667067 CMS
E.R. Squibb & Sons, L.L.C. $138.8605/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014667079 CMS
EMD Serono, Inc. $24.3305/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032523069 CMS
Horizon Therapeutics plc $124.9905/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 986951801 CMS
Horizon Therapeutics plc $2,750.0005/09/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 986951805 CMS
TG Therapeutics, Inc. $830.6305/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051492499 CMS
TG Therapeutics, Inc. $3,300.0005/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051492555 CMS
TG Therapeutics, Inc. $95.4005/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051492791 CMS
AbbVie Inc. $19.7405/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996225961 CMS
Genentech USA, Inc. $24.5005/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040335647 CMS
TG Therapeutics, Inc. $24.7605/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051492681 CMS
GENZYME CORPORATION $1,460.0005/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050102519 CMS
E.R. Squibb & Sons, L.L.C. $99.2505/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014666951 CMS
TG Therapeutics, Inc. $3,200.0004/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051492747 CMS
AbbVie Inc. $9.0004/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996225957 CMS
AbbVie Inc. $6.4004/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996225959 CMS
Celgene Corporation $17.6704/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014666963 CMS
E.R. Squibb & Sons, L.L.C. $3,680.0004/26/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014666915 CMS
Biogen, Inc. $79.6104/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012237907 CMS
Horizon Therapeutics plc $94.6704/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 986951799 CMS
Novartis Pharmaceuticals Corporation $86.3504/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991435487 CMS
EMD Serono, Inc. $86.5204/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032589853 CMS
Celgene Corporation $129.1204/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014666975 CMS
Genentech USA, Inc. $88.0304/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040335537 CMS
Genentech USA, Inc. $0.4004/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040335597 CMS
Genentech USA, Inc. $0.3604/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040335615 CMS
Genentech USA, Inc. $26.3704/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040335627 CMS
Lilly USA, LLC $6.2604/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031328703 CMS
PFIZER INC. $6.0804/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049181161 CMS
AbbVie Inc. $6.5104/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996225955 CMS
Celgene Corporation $461.8004/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014666927 CMS
BANNER LIFE SCIENCES, LLC $19.3504/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021110229 CMS
TG Therapeutics, Inc. $125.0004/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051492577 CMS
TG Therapeutics, Inc. $3,300.0004/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051492865 CMS
TG Therapeutics, Inc. $131.0004/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051492899 CMS
TG Therapeutics, Inc. $173.6304/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051492909 CMS
E.R. Squibb & Sons, L.L.C. $53.5904/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014667045 CMS
E.R. Squibb & Sons, L.L.C. $154.9204/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014667091 CMS
EMD Serono, Inc. $22.8504/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032488645 CMS
Horizon Therapeutics plc $25.8704/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 986951795 CMS
PFIZER INC. $5.2904/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049681147 CMS
AbbVie Inc. $6.2204/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996225951 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $438,522.97 468
PY2020 $122,356.95 227
PY2021 $134,302.91 343
PY2022 $280,742.36 558
PY2023 $215,638.63 397
PY2024 $226,720.09 418
PY2025 $164,667.41 362

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $94,506.85 153
PY2024 Recipient $2,630.78 14
PY2024 Principal investigator $163,714.97 178
PY2023 Principal investigator $286,926.29 154
PY2022 Principal investigator $685,048.30 34
PY2021 Principal investigator $707,002.02 33
PY2020 Principal investigator $648,302.85 44
PY2019 Recipient $1,087.63 9
PY2019 Principal investigator $61,903.76 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

153 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $80.00 11/14/2025 Non-covered Recipient Entity
International Neurorehabilitation Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226134252
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616872
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616875
Principal investigator 1 Roche Products Limited $211.50 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616878
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616883
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616886
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616889
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616893
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616897
Principal investigator 1 Genentech, Inc. $4,457.00 09/19/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211616916
Principal investigator 1 Genentech, Inc. $1,277.00 09/18/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211616912
Principal investigator 1 GENZYME CORPORATION $5,400.00 09/17/2025 Non-covered Recipient Entity
Internationall Neuro Rehabilitation Institute
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226147395
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616550
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616554
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616559
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616563
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616566
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616571
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616574
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616579
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616584
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616587
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616592
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616595
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616600
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616604
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616608
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616613
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616620
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616624
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616628
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616632
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616636
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616639
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616644
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616647
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616652
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616656
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616660
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616664
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616669
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616673
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616677
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616681
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616686
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616690
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616694
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616699
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616703
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616707
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616711
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616717
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616721
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616723
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616727
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616731
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616734
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616739
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616742
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616747
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616752
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616757
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616761
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616765
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616768
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616772
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616776
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616780
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616788
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616792
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616797
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616800
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616804
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616808
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616812
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616816
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616820
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616825
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616829
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616834
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616837
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616841
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616844
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616849
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616854
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616858
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616862
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616868
Principal investigator 1 Genentech, Inc. $4,885.90 06/10/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211616900
Principal investigator 1 GENZYME CORPORATION $13,050.00 06/09/2025 Non-covered Recipient Entity
Internationall Neuro Rehabilitation Institute
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226094053
Principal investigator 1 Genentech, Inc. $26,455.00 04/15/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211616903
Principal investigator 1 Genentech, Inc. $4,850.45 04/03/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211616908
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616310
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616313
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616315
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616320
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616323
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616331
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616335
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616339
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616344
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616348
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616353
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616358
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616372
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616376
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616381
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616384
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616387
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616389
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616396
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616400
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616405
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616410
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616415
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616419
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616423
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616426
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616430
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616434
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616438
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616445
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616449
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616453
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616461
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616465
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616469
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616472
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616477
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616491
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616495
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616499
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616503
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616508
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616512
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616519
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616523
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616526
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616533
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616537
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616546
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616317
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616327
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616365
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616369
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616392
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616442
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616458
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616481
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616485
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616515
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616530
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616542